海利尔药业集团股份有限公司独立董事关于 第五届董事会第一次会议有关事项的独立意见 根据《公司法》《公司章程》和《海利尔药业集团股份有限公司独立董事 工作制度》的规定，作为海利尔药业集团股份有限公司（以下简称"公司"）的 独立董事，本着认真、负责的态度，我们对公司本次会议相关事项进行了充分 的审查。经认真审阅文件后，基于我们的独立判断，现就相关事项发表如下独 立意见： 一、关于选举公司董事长、聘任总经理及其他高级管理人员的独立意见 1、经审阅相关人员简历，其任职资格符合《公司法》《公司章程》中关于 董事长、高级管理人员任职资格的规定； 2、公司董事长的选举、高级管理人员的聘任程序合法、合规； 3、同意选举葛家成先生为董事长兼总经理，刘玉龙先生为财务负责人，迟 明明女士为董事会秘书。 （本页以下无正文） （此页无正文，为海利尔药业集团股份有限公司独立董事关于第五届董事会第 一次会议有关事项的独立意见签字页） _______ ___ 独立董事签字： （杨爱义） 年 月 日 （此页无正文，为海利尔药业集团股份有限公司独立董事关于第五届董事会第 一次会议有关事项的独立意见签字页） 独立董事签字： _______ ___ ...

证券代码：603639 证券简称：海利尔 公告编号：2023-045 海利尔药业集团股份有限公司 关于公司第五届董事会第一次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 海利尔药业集团股份有限公司(以下简称"公司")第五届董事会第一次会议 于 2023 年 8 月 28 日在公司五楼会议室以现场和通讯相结合的方式召开。会议通 知于 2023 年 8 月 18 日以电子邮件的方式发出，会议应出席董事 9 名，实际出席 董事 9 名。会议由董事长葛家成主持，公司监事、高级管理人员列席了会议。本 次会议的召集和召开符合《中华人民共和国公司法》和《海利尔药业集团股份有 限公司章程》的有关规定，会议决议合法有效。 二、董事会会议审议情况 1.审议通过《关于选举公司董事长的议案》 同意选举葛家成先生为公司董事长，任期至本届董事会届满之日止。 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 2.审议通过《关于聘任公司终身名誉董事长的议案》 同意聘任葛尧伦先生为公司终身名誉董事长。 葛尧伦 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 海利尔药业集团股份有限公司(以下简称"公司")第五届监事会第一次会议 于 2023 年 8 月 28 日 10：00 在青岛市城阳区国城路 216 号，公司五楼会议室召 开。会议通知于 2023 年 8 月 18 日以电子邮件的方式发出。会议应出席监事 3 名，实际出席监事 3 名，公司董事会秘书列席会议。本次会议的召集和召开符合 《中华人民共和国公司法》和《海利尔药业集团股份有限公司章程》的有关规定， 会议决议合法有效。会议由陈萍先生主持，经与会监事充分审议，本次会议形成 如下决议： 二、 监事会会议审议情况 证券代码：603639 证券简称：海利尔 公告编号：2023-046 海利尔药业集团股份有限公司 关于公司第五届监事会第一次会议决议的公告 3、审议通过《关于公司 2023 年半年度主要经营数据的议案》 具体内容详见 2023 年 8 月 29 日在《上海证券报》及上海证券交易所网站 （www.sse.com.cn）披露的《关于公司 2023 年半 ...

北京市金杜（青岛）律师事务所 关于海利尔药业集团股份有限公司 2023 年第一次临时股东大会之法律意见书 致：海利尔药业集团股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受海利尔药业集团股份 有限公司（以下简称公司或海利尔）的委托，根据《中华人民共和国公司法》 （以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、 《上市公司股东大会规则（2022年修订）》（以下简称《股东大会规则》）等中 华人民共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香 港特别行政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法 规、规章和规范性文件以及现行有效的《海利尔药业集团股份有限公司章程》 （以下简称《公司章程》）的有关规定，指派律师出席了公司于2023年8月25日 召开的2023年第一次临时股东大会（以下简称本次股东大会），并就本次股东大 会的相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 公司 2022 年年度股东大会审议通过的《公司章程》； 2. 公司 2023 年 8 月 8 日披露于巨潮资讯网（http ...

证券代码：603639 证券简称：海利尔 公告编号：2023-044 海利尔药业集团股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 (二) 股东大会召开的地点：青岛市城阳区国城路 216 号公司五楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 13 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 224,273,962 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 65.9182 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长葛尧伦先生因出差在外无法出席本 次会议，经过半数以上董事推举董事葛家成先生代为主持会议。会议采取现场投 票及网络投票相结合的方式召开并表决。其中：出席本次股东大会现场会议的股 东 ...

海利尔药业集团股份有限公司 2023 年第一次临时股东大会 会议材料 二〇二三年八月二十五日 （一）会议类型和届次：2023 年第一次临时股东大会 （二）会议召开时间、地点： 会议时间：2023 年 8 月 25 日 14:30-16:00 会议地点：青岛市城阳区国城路 216 号五楼会议室 （三）会议出席人员 1、股东、股东代表 2、公司董事、监事和高级管理人员 3、公司聘请的律师 4、其他人员 （一）全体与会股东或股东代表、列席会议的董事、监事、高级管理人员签到； （二）报告会议出席情况，宣布会议开始； （三）本次股东大会各项议案宣读并审议； （四）股东或股东代表发言及公司董事、监事、高级管理人员回答提问； （五）记名投票表决（由股东、监事及律师组成的表决统计小组进行统计）； （六）与会代表休息（工作人员统计现场投票结果），等待接收网络投票结果； （七）网络投票结果产生后，宣读投票结果和决议； （八）律师宣读本次股东大会法律意见书，董事在股东大会决议及会议记录上签字； （九）宣布会议结束。 海利尔药业集团股份有限公司 2023 年第一次临时股东大会会议须知 为了维护海利尔药业集团股份有限公司（以下简称"公 ...

证券代码：海利尔 证券简称：603639 公告编号：2023-029 海利尔药业集团股份有限公司 关于召开2022年度暨2023年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 会议召开方式：上证路演中心网络互动 投资者可于2023年05月22日(星期一) 至05月26日(星期五)16:00前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱hailir@hailir.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 海利尔药业集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发 布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营 成果、财务状况，公司计划于 2023 年 05 月 29 日 下午 16:00-17:00 举行 2022 年度暨 2023 年第一季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果及 财务指标的具体情况与投 ...

Financial Performance - The company's operating revenue for 2022 reached ¥4,534,999,014.48, representing a 22.60% increase compared to ¥3,698,878,563.93 in 2021[24]. - The net profit attributable to shareholders for 2022 was ¥460,009,892.48, a 2.28% increase from ¥449,745,299.66 in 2021[24]. - The net cash flow from operating activities increased by 58.45% to ¥694,685,709.15 in 2022, up from ¥438,414,771.60 in 2021[25]. - Total assets at the end of 2022 were ¥5,837,602,158.84, a 13.57% increase from ¥5,140,249,797.15 at the end of 2021[25]. - The basic earnings per share for 2022 was ¥1.35, slightly up from ¥1.33 in 2021, marking a 1.50% increase[26]. - The diluted earnings per share also stood at ¥1.35 for 2022, consistent with the previous year[26]. - The weighted average return on equity decreased to 14.83% in 2022 from 15.93% in 2021, a reduction of 1.10 percentage points[26]. - The net assets attributable to shareholders increased to ¥3,211,952,919.85 at the end of 2022, a 5.65% rise from ¥3,040,203,246.83 at the end of 2021[25]. Dividend Policy - The company plans to distribute a cash dividend of 10 CNY per 10 shares to all shareholders, subject to approval at the shareholders' meeting[6]. - The total cash dividend amount for the fiscal year is 340,230,446.00 RMB, which represents 73.96% of the net profit attributable to ordinary shareholders in the consolidated financial statements[198]. - The company has a fixed cash dividend policy, distributing at least 10% of the distributable profits in a single fiscal year, with higher percentages based on the company's development stage and capital expenditure plans[193][194]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[8]. - The company has a comprehensive risk management strategy in place to address potential operational risks[8]. - The company faces risks related to safety production and environmental protection, particularly due to the nature of its chemical products[150]. - The company is addressing the volatility of raw material prices and production instability by increasing investment in technological upgrades and monitoring raw material price trends[152]. - The company is enhancing procurement strategies to mitigate risks associated with upstream raw material supply and price fluctuations[153]. Research and Development - The company is focused on expanding its market presence and enhancing its research and development capabilities for new products[18]. - Research and development expenses increased by 43.31% to CNY 234,055.75 million, reflecting a focus on new project development[64]. - The company is committed to increasing R&D investment to develop differentiated, environmentally friendly pesticide formulations to combat market competition[155]. - The company aims to enhance its R&D capabilities, aiming to build a first-class R&D team and develop forward-looking new compounds[139]. - The company has filed over 80 patents and 104 trademarks, receiving the highest honor for intellectual property management from the state[101]. Market Expansion - The company is actively exploring international markets to mitigate risks and create new growth points through diversified product offerings[44]. - The company is expanding its overseas market presence, having obtained nearly 1,800 product registration certificates in over 30 countries, including Paraguay and Egypt[60]. - The company is focusing on international market expansion, enhancing brand effect, and improving sales channels for self-produced raw materials and strategic products[147]. Production and Operations - The company produced 48,047.32 tons of pesticides, with a sales volume of 46,912.43 tons, indicating a production increase of 7.42%[69]. - The company has ongoing projects expected to complete by December 2023 and 2027, including a 20,000-ton and a 50,000-ton pesticide formulation project[114]. - The design capacity for pesticide production is 80,400 tons, with a current utilization rate of 60%[114]. - The company has completed the trial production of a new 3,000-ton pesticide project, with ongoing adjustments and upgrades to production processes[115]. Corporate Governance - The company has established a robust corporate governance structure, ensuring compliance with relevant laws and regulations to protect shareholder rights[160]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirement of at least one-third independence[161]. - The company has a total of 8 independent directors, contributing to governance and oversight[169]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 607.81 million yuan[175]. Employee Management - The total number of employees in the parent company is 596, while the total number of employees in major subsidiaries is 2,296, resulting in a combined total of 2,892 employees[189]. - The company has implemented a stock incentive policy to share the results of corporate development with employees[190]. - The company maintains a salary policy that emphasizes strategic orientation, internal fairness, and external competitiveness[190]. - The company has implemented a talent training program, focusing on new employees and key positions, to enhance professional skills and career development[191].

[Financial Summary and Operating Analysis](index=1&type=section&id=Item%201.%20Key%20Financial%20Data) This section details the company's core financial performance, non-recurring items, and the underlying reasons for significant financial metric fluctuations [Core Financial Indicators](index=1&type=section&id=Item%201.%281%29%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In Q1 2023, the company reported operating revenue of 1.23 billion Yuan and net profit of 152 million Yuan, with total assets reaching 6.205 billion Yuan, indicating stable growth Key Financial Data for Q1 2023 | Indicator | Current Period (Yuan) | YoY Change (%) | | :--- | :--- | :--- | | Operating Revenue | 1,229,872,265.99 | 2.51% | | Net Profit Attributable to Shareholders | 152,156,390.34 | 6.69% | | Net Cash Flow from Operating Activities | 147,905,383.19 | N/A | | Basic Earnings Per Share (Yuan/share) | 0.45 | 6.43% | | **Indicator** | **End of Current Period (Yuan)** | **Change from Prior Year-End (%)** | | Total Assets | 6,204,612,121.46 | 6.29% | | Owners' Equity Attributable to Shareholders | 3,372,103,540.07 | 4.99% | [Non-recurring Gains and Losses Analysis](index=2&type=section&id=Item%201.%282%29%20Non-recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) During the reporting period, the company's non-recurring gains and losses totaled 3.16 million Yuan, primarily from government grants and fair value changes Details of Non-recurring Gains and Losses | Item | Amount (Yuan) | | :--- | :--- | | Government Grants Recognized in Current P&L | 5,133,430.67 | | Fair Value Changes from Financial Assets Held for Trading | 528,649.75 | | Gains/Losses on Disposal of Non-current Assets | -314,293.25 | | Other Non-operating Income and Expenses | -1,355,807.94 | | **Total** | **3,157,537.21** | [Reasons for Major Financial Indicator Changes](index=3&type=section&id=Item%201.%283%29%20Changes%20and%20Reasons%20for%20Major%20Accounting%20Data%20and%20Financial%20Indicators) Significant financial metric fluctuations were observed, including a 31.56% increase in accounts receivable and a 2720.59% surge in financial expenses due to exchange rate changes Major Financial Indicator Changes and Reasons | Item Name | Change (%) | Primary Reason | | :--- | :--- | :--- | | Accounts Receivable | 31.56 | Increase in receivables due to peak shipping season | | Construction in Progress | 49.42 | New construction projects | | Taxes Payable | 394.12 | Accrual of Q1 corporate income tax | | Financial Expenses | 2,720.59 | Exchange rate fluctuations impacting exchange gains/losses | | Investment Income | 1,111.79 | Difference between forward exchange settlement price and current exchange rate | | Asset Impairment Losses | 32,767.18 | Provision for impairment of raw material inventory | [Shareholder Structure and Holdings](index=4&type=section&id=Item%202.%20Shareholder%20Information) This section outlines the company's shareholder composition, including the total number of shareholders and the detailed holdings of its top shareholders [Major Shareholder Holdings](index=4&type=section&id=Item%202.%281%29%20Total%20Common%20Shareholders%2C%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders%27%20Holdings) As of the reporting period end, the company had 10,625 common shareholders, with significant control held by the top two shareholders, Zhang Aiying and Ge Yaolun - At the end of the reporting period, the total number of common shareholders was **10,625**[11](index=11&type=chunk) Top Four Shareholder Holdings | Shareholder Name | Number of Shares Held (shares) | Shareholding Percentage (%) | Shareholder Type | | :--- | :--- | :--- | :--- | | Zhang Aiying | 127,253,000 | 37.40 | Domestic Natural Person | | Ge Yaolun | 62,010,588 | 18.23 | Domestic Natural Person | | Qingdao Heyi Investment Center (Limited Partnership) | 17,744,951 | 5.22 | Domestic Non-State-Owned Legal Person | | Ge Jiacheng | 12,725,300 | 3.74 | Domestic Natural Person | - Shareholders Zhang Aiying, Ge Yaolun, and Ge Jiacheng are parties acting in concert. Zhang Aiying has pledged **20,000,000** of her shares[11](index=11&type=chunk)[12](index=12&type=chunk) [Financial Statements](index=5&type=section&id=Item%204.%20Quarterly%20Financial%20Statements) This section presents the company's consolidated balance sheet, income statement, and cash flow statement for the reporting period [Consolidated Balance Sheet](index=5&type=section&id=Item%204.%282%29%20Financial%20Statements-Consolidated%20Balance%20Sheet) As of March 31, 2023, total assets reached 6.205 billion Yuan and total liabilities 2.833 billion Yuan, reflecting a stable and growing financial structure Key Balance Sheet Items (Yuan) | Item | March 31, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Total Assets** | **6,204,612,121.46** | **5,837,602,158.84** | | Total Current Assets | 3,329,924,986.41 | 2,952,025,948.79 | | Total Non-current Assets | 2,874,687,135.05 | 2,885,576,210.05 | | **Total Liabilities** | **2,832,508,581.39** | **2,625,649,238.99** | | Total Current Liabilities | 2,570,357,803.96 | 2,421,550,178.69 | | Total Non-current Liabilities | 262,150,777.43 | 204,099,060.30 | | **Total Owners' Equity** | **3,372,103,540.07** | **3,211,952,919.85** | [Consolidated Income Statement](index=8&type=section&id=Item%204.%282%29%20Financial%20Statements-Consolidated%20Income%20Statement) In Q1 2023, total operating revenue was 1.23 billion Yuan, with net profit attributable to parent company shareholders reaching 152 million Yuan, indicating stable profitability Key Income Statement Items (Yuan) | Item | Q1 2023 | Q1 2022 | | :--- | :--- | :--- | | Total Operating Revenue | 1,229,872,265.99 | 1,199,790,300.43 | | Total Operating Costs | 1,017,504,033.58 | 1,020,930,564.90 | | Of which: R&D Expenses | 64,369,603.40 | 50,018,468.83 | | Financial Expenses | 15,592,833.80 | 552,821.03 | | Operating Profit | 176,234,285.06 | 167,805,090.20 | | **Net Profit Attributable to Parent Company Shareholders** | **152,156,390.34** | **142,614,951.22** | [Consolidated Cash Flow Statement](index=10&type=section&id=Item%204.%282%29%20Financial%20Statements-Consolidated%20Cash%20Flow%20Statement) Net cash flow from operating activities significantly improved to a 148 million Yuan inflow in Q1 2023, with total cash and equivalents increasing to 650 million Yuan Key Cash Flow Statement Items (Yuan) | Item | Q1 2023 | Q1 2022 | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 147,905,383.19 | -19,665,221.37 | | Net Cash Flow from Investing Activities | 146,172,919.35 | -103,665,206.47 | | Net Cash Flow from Financing Activities | -228,046.91 | 20,002,971.70 | | Net Increase in Cash and Cash Equivalents | 287,161,646.38 | -98,763,697.61 | | Cash and Cash Equivalents at Period End | 650,129,364.93 | 414,745,217.90 |

Financial Performance - The company's operating revenue for Q3 2022 was approximately CNY 992 million, representing a year-on-year increase of 59%[5] - The net profit attributable to shareholders for the same period was approximately CNY 101 million, reflecting a growth of 22.68% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses reached approximately CNY 162 million, marking a significant increase of 102.18% year-on-year[5] - The company's basic earnings per share for Q3 2022 was CNY 0.29, up by 20.83% year-on-year[6] - Total operating revenue for the first three quarters of 2022 reached ¥3,802,550,062.12, a significant increase of 47.2% compared to ¥2,583,248,784.10 in the same period of 2021[18] - Net profit for the first three quarters of 2022 was ¥430,591,861.86, representing a 38.4% increase from ¥311,107,833.01 in the same period of 2021[19] - The company’s total comprehensive income for the third quarter of 2022 was ¥430,518,267.23, up from ¥311,108,669.27 in the same quarter of 2021[20] Cash Flow - The cash flow from operating activities for the year-to-date period was approximately CNY 303 million, showing a growth of 103.02%[6] - Cash flow from operating activities for the first three quarters of 2022 was ¥303,218,727.76, an increase of 102.3% from ¥149,356,093.59 in 2021[23] - The company reported a net cash flow from investment activities of -¥555,269,883.47 for the first three quarters of 2022, worsening from -¥226,801,530.60 in 2021[23] - The company received cash from financing activities amounting to ¥1,067,529,165.01 in the first three quarters of 2022, compared to ¥344,463,484.58 in 2021[23] - The net cash flow from financing activities was $327,499,464.15, an increase from $127,746,540.17 in the previous year, representing a growth of approximately 156%[24] Assets and Liabilities - The total assets at the end of the reporting period amounted to approximately CNY 6.39 billion, an increase of 24.34% from the end of the previous year[6] - As of September 30, 2022, the total assets of the company reached RMB 6,391,442,791.35, an increase from RMB 5,140,249,797.15 at the end of 2021, representing a growth of approximately 24.4%[16] - The company's current assets totaled RMB 3,725,035,612.34, up from RMB 2,887,036,129.95, indicating an increase of about 29.1% year-over-year[14] - The company's total liabilities increased to RMB 3,209,775,706.44 from RMB 2,100,046,550.32, which is an increase of approximately 52.9%[16] - The total equity attributable to shareholders reached RMB 3,181,667,084.91, up from RMB 3,040,203,246.83, representing an increase of about 4.7%[16] Investments and Expenses - Research and development expenses increased by 51.16%, indicating a commitment to enhancing R&D investment[10] - The company reported a significant increase in accounts receivable by 98.36%, attributed to expanded revenue scale[10] - The company experienced a 244.52% increase in short-term borrowings, primarily due to bank acceptance bill discounting[10] - The company reported a short-term loan of RMB 1,068,000,000.00, significantly higher than RMB 310,000,000.00 in the previous year, indicating a rise of approximately 244.8%[15] - Total operating costs for the first three quarters of 2022 were ¥3,180,955,439.46, up 43.6% from ¥2,214,384,949.26 in 2021[19] Cash and Equivalents - Cash and cash equivalents amounted to RMB 992,136,145.00, compared to RMB 840,958,760.09 in the previous year, reflecting a growth of approximately 17.9%[14] - The cash and cash equivalents at the end of the period reached $605,750,856.27, up from $438,218,084.92, reflecting a net increase of $92,241,940.76[24] - The impact of exchange rate changes on cash and cash equivalents was $16,793,632.32, compared to $7,688,017.05 in the previous year, showing an increase of approximately 118%[24] - The beginning balance of cash and cash equivalents was $513,508,915.51, which is higher than the previous year's balance of $380,228,964.71[24]